SUBSCRIBE
SUBSCRIBE

Immunic Therapeutics

NEWS
Multiple sclerosis damaged myelin or MS autoimmune disease with healthy nerve with exposed fibre with scarrred cell sheath loss as a 3D illustration.
Multiple sclerosis
Beyond BTK Inhibitors: Next Gen MS Treatments Could Transcend Symptom Management
While Bruton’s tyrosine kinase inhibitors are often hailed as the next big breakthrough in multiple sclerosis, Immunic Therapeutics and others are leveraging neuroprotective targets and remyelination to keep the disease at bay.
October 6, 2025
 · 
5 min read
 · 
Ben Hargreaves
IN THE PRESS
Press Releases
Immunic to Participate in Scientific and Industry Conferences in May 2025
May 2, 2025
 · 
6 min read
Press Releases
Immunic Announces Vidofludimus Calcium Reduced Risk of Disability Worsening by 30% in Primary Progressive Multiple Sclerosis Patients from Phase 2 CALLIPER Trial
April 30, 2025
 · 
14 min read
Press Releases
Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments
April 11, 2025
 · 
6 min read
Press Releases
Immunic, Inc. to Participate in Scientific and Industry Conferences in April
April 1, 2025
 · 
5 min read
Press Releases
Immunic to Participate in Scientific and Investor Conferences in March
March 3, 2025
 · 
6 min read
Press Releases
Immunic Presents Key Vidofludimus Calcium Data at the ACTRIMS Forum 2025, Highlighting Its Potential in Multiple Sclerosis
February 27, 2025
 · 
8 min read
Press Releases
Immunic’s Oral IMU-856 Demonstrated Dose-Dependent Increase of GLP-1 in Celiac Disease Patients and Corresponding Effects in Preclinical Testing
February 21, 2025
 · 
11 min read
Press Releases
Immunic to Participate in Investor and Scientific Conferences in February
February 4, 2025
 · 
8 min read
Press Releases
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
January 8, 2025
 · 
11 min read
Press Releases
Immunic, Inc. to Participate in Investor Conference in December
November 26, 2024
 · 
5 min read
Load More
JOBS